A Randomized Trial Evaluating a mRNA VLP vaccine’s Immunogenicity and Safety for COVID-19 - ARTEMIS-C

Study identifier:D8670C00001

ClinicalTrials.gov identifier:NCT06147063

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I, Open-label, Randomized, Active-Controlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine (ARTEMIS-C)

Medical condition

COVID-19

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

All

Estimated Enrollment

90

Study type

Interventional

Age

18 Years - 64 Years

Date

Study Start Date: 27 Nov 2023
Estimated Primary Completion Date: 12 Feb 2024
Estimated Study Completion Date: 10 Apr 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria